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Impaired diversity of the lung microbiome
predicts progression of idiopathic
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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe form of idiopathic interstitial
pneumonias. Although IPF has not been thought to be associated with bacterial communities, recent papers
reported the possible role of microbiome composition in IPF. The roles of microbiomes in respiratory functions and
as clinical biomarkers for IPF remain unknown. In this study, we aim to identify the relationship between the
microbial environment in the lung and clinical findings.
Methods: Thirty-four subjects diagnosed with IPF were included in this analysis. The 16S rDNA was purified from
bronchoalveolar lavage fluid obtained at the time of diagnosis and analyzed using next-generation sequencing
techniques to characterize the bacterial communities. Furthermore, microbiomes from mice with bleomycin-
induced lung fibrosis were analyzed.
Results: The most prevalent lung phyla were Firmicutes, Proteobacteria and Bacteroidetes. Decreased microbial
diversity was found in patients with low forced vital capacity (FVC) and early mortality. Additionally, the diversity
and relative abundance of Firmicutes, Streptococcaceae, and Veillonellaceae were significantly associated with FVC,
6-min walk distance, and serum surfactant protein D. Bleomycin-induced lung fibrosis resulted in decrease of
diversity and alteration of microbiota in PCoA analysis. These results support the observations in human specimens.
Conclusions: This study identified relationships between specific taxa in BALF and clinical findings, which were also
supported by experiments in a mouse model. Our data suggest the possibility that loss of microbial diversity is
associated with disease activities of IPF.
Keywords: Idiopathic pulmonary fibrosis, Microbiome, Next-generation sequencing techniques, Bleomycin, Mouse
model, Diversity, Disease progression, Surfactant protein
Background
Idiopathic pulmonary fibrosis (IPF) is a well-known life-
threatening disease of the lung with median survival of
only 3 to 5 years [1–3] Patients with IPF exhibit restrict-
ive ventilatory impairment caused by progressive lung fi-
brosis, and a decline in forced vital capacity (FVC) is
strongly associated with mortality [4]. Among the vari-
ous forms of idiopathic interstitial pneumonias, IPF has
attracted the most attention because of its poor progno-
sis and the limited number of therapeutic agents. In
addition, acute exacerbation (AE) is the most critical
life-threatening event in IPF, especially in Asians, includ-
ing Japanese [5–7]. Many studies have identified key fac-
tors in the development of IPF, and some drugs against
fibrosis have been developed, but the direct cause re-
mains unknown [8, 9].
Until recently, the lung was considered to be a sterile
compartment because culture-based techniques are lim-
ited in their ability to identify all bacteria that may be
present. However, new techniques have been developed
that have identified bacterial communities both in
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healthy humans and those with pulmonary diseases
[10–12]. This new characterization of the lung micro-
biome is likely to provide important pathogenic in-
sights into chronic lung diseases, including cystic
fibrosis, chronic obstructive pulmonary disease, and
asthma. Recent papers have reported the possible role of
microbiome composition in IPF [13, 14]. Increased bacter-
ial burden and presence of specific bacteria have been as-
sociated with disease progression. However, the roles of
the microbiome in respiratory functions and as a clinical
marker in IPF remain unknown.
In the current study, we performed a retrospective
comprehensive analysis of lower respiratory tract bacter-
ial microbiomes in Japanese individuals with IPF. To in-
vestigate the clear relationship between microbiome and
pathological conditions, we also analyzed microbiome




The subjects who were retrospectively included in this
analysis were IPF patients who had visited Sapporo
Medical University Hospital. The study was approved by
the hospital’s ethics board (approval number, 292–35).
Diagnosis of IPF was performed according to the ATS/
ERS/JRS/ALAT statement 2011 [2]. In this study, drug
history (discussed in the Results section) is not included
in the exclusion criteria. The patient characteristics, re-
sults of pulmonary function tests, arterial blood gas ana-
lysis, and 6-min walk distance (6MWD) test, as well as
general blood test and some biomarkers for IPF in
serum at enrollment were investigated. The pulmonary
function test (PFT), including determination of the FVC
and diffusing capacity of lung carbon monoxide (DLco),
was performed by using a CHESTAC-55 V system
(CHEST M.I., Inc., Tokyo, Japan). The 6MWD test was
performed in accordance with ATS guidelines. The GAP
(gender, age, and physiological variables) point score was
calculated by determining the subject’s gender, age in
years, percent predicted FVC (%FVC), and percent pre-
dicted DLCO (%DLCO), as described previously [15]. PFT
results at 12 ± 1 months from baseline and the change in
FVC were evaluated. Deterioration was defined as a ≥ 10%
relative decline in FVC from baseline and severe respira-
tory status in which PFTs were unable to be performed
[16]. AE was defined according to the Japanese criteria
[16]. These criteria are consistent with the criteria pro-
posed by Collard and coworkers in 2007 [17].
Sample collection
Bronchoscopy was performed in patients with clinically
diagnosed IPF. The bronchoscope was inserted via the
mouth and through the vocal cords. After carefully
observing the lumen of the bronchus, the bronchoscope
was wedged into a targeted lobe using an intubation
tube. Bronchoalveolar lavage (BAL) was performed in ei-
ther the middle lobe or the lingula, irrespective of the
imaging abnormality on high-resolution computed tom-
ography (HRCT). BAL was performed with 3 instilla-
tions of 50 ml of warmed normal saline for a total of
150 ml with all possible returns collected and pooled.
Samples for microbiome analysis were added to a falcon
tube and stored at − 80 °C until the time of DNA
extraction.
Murine model
C57BL/6 J mice were purchased from Sankyo Labo
Service Corporation Inc. (Tokyo, Japan). We ensured
that they were equivalent in genetic quality and had
stable phenotypes. Although non-littermate mice might
have different microbial flora, we did not use littermates
in this study to avoid a bias arising from the residing
genetic inheritance. In addition to similar housing condi-
tions provided to all animals, including food, water and
co-house, the random selection ensured elimination of
the bias as much as possible. The mice were maintained
under specific pathogen-free conditions and used when
they were 8 weeks of age. Thereafter, we divided the
mice into two groups: bleomycin and normal saline
groups. Bleomycin hydrochloride (Nippon kayaku Co.,
Tokyo, Japan) was dissolved in normal saline and con-
tinuously administrated via micro-osmotic pump (Alzet
1007D; DURECT Corporation, CA). Mice were anesthe-
tized by inhalation of isoflurane, followed by Alzet pump
insertion into the mid-back subcutaneous region. Alzet
pumps contained either 100 μl of bleomycin hydrochlor-
ide (100 mg/kg) or normal saline as a control, and were
designed to deliver their contents at 0.5 μL/h over 7 days.
At 28 days after Alzet pump insertion, mice were sacri-
ficed with an intraperitoneal injection of pentothal, and
blood was immediately collected for obtaining serum
samples. Lungs were lavaged with 1 ml of normal saline.
For histological examination, lungs were fixed with 10%
formalin phosphate and embedded in paraffin. Lung sec-
tions were stained with hematoxylin-eosin and Masson
trichrome reagent, and examined with a microscope.
Total and differential cells in the bronchoalveolar lavage
fluid (BALF) were counted using the XT-1800iV (Sys-
mex, Japan). All experiments using mice were conducted
according to the regulations of the Sapporo Medical
University Animal Care and Use Committee.
Standard lysis protocol and DNA isolation
A 1.5 ml aliquot of the BALF sample was centrifuged at
10,000 g for 10 min, and the supernatant was discarded.
The pellets were suspended in 180 μl of lysis solution
(20 mg/ml egg chicken lysozyme (Sigma-Aldrich),
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20 mM Tris-HCl (pH 7.4), 2 mM EDTA, 1.2% Triton
X), then incubated for 30 min at 37 °C with occasional
vortex mixing. Samples were digested by Proteinase K
(final concentration, 1 mg/mL) and incubated for
30 min at 65 °C. DNA purification was performed using
a DNeasy Blood and Tissue Kit (Qiagen) per manufac-
turer instructions.
Real-time polymerase chain reaction (PCR)
The number of tuf gene expression was analyzed to esti-
mate the number of bacteria in the BALF. Real-time
PCR was performed on these samples by using a bacter-
ial quantitative PCR kit (Takara, Japan) and a 7900 HT
Fast Real-Time PCR System (Applied Biosystems). The
cycling conditions were 1 cycle at 95 °C for 30 s, 35 cy-
cles at 95 °C for 5 s, and 60 °C for 30 s.
DNA sequencing and sequence analyses
An Ion 16S Metagenomics Kit, which is designed for
rapid analyses of bacterial samples using Ion Torrent se-
quencing technology, was used for the sequencing ana-
lysis of the bacterial 16S rDNA gene. This kit includes 2
primer sets that selectively amplify the corresponding
hypervariable regions of the 16S region in bacteria: V2–
4-8 and V3–6, 7–9. The primary PCR cycling conditions
were 95 °C for 10 min, followed by 27 cycles of standard
PCR (95 °C for 30 s, 50 °C for 30 s, and 72 °C for 45 s),
and finished with 72 °C for 7 min. Then, sequence ana-
lyses were performed by using the Ion Torrent sequen-
cing platform (Ion Torrent PGM™). Raw sequencing data
were processed by using the mother software package,
as described in the Ion Torrent standard operating pro-
cedure. After sequencing, raw signal data were analyzed
using Torrent Suite version 5.0. The pipeline included
signaling processing, base calling, low quality read re-
moval, and adapter trimming. Sequencing data in BAM
format were further processed using Ion Reporter soft-
ware v5.2. These files, with the taxonomic information
for the operational taxonomic units (OTUs), were
imported and further analyzed using Explicet v2.10 soft-
ware (Robertson, http://www.explicet.org). We restricted
the principal components and regression analyses to
OTUs that were present at > 1.0% of a given sample’s
population and taxonomically identifiable.
Statistical analysis
Continuous variables are shown as the median with
interquartile ranges. For comparisons between two
groups, continuous variables were examined by using
the Mann–Whitney U test on GraphPad Prism v7 soft-
ware (GraphPad, Inc., San Diego, CA, USA). Alpha-
diversity metrics were used to characterize the bacterial
diversity within each sample. Alpha-diversity metrics, in-
cluding the Shannon diversity index and Simpson
diversity (1-D) index, were computed by using Explicet
v2.10 software. Spearman’s correlation analysis and JMP
13.0 (SAS Institute, Cary, NC, USA) were used to evaluate
the coefficients of determination (ρ), residuals, and signifi-
cance (p) to identify associations between the microbiome
and parameters. Principal coordinates analysis (PCoA) of
the Bray-Curtis dissimilarity between samples was gener-
ated using Past v3.13 software (Hammer O. Past 3.× 2017.
Available from: http://folk.uio.no/ohammer/past/).
Results
Patient characteristics and clinical data
The subjects included in this analysis are shown in
Table 1. Thirty-four patients with suspected IPF were
enrolled in this study from July 2013 to December 2015
and underwent bronchoscopy. A diagnosis of IPF was
made by ≥3 pulmonologists on the basis of HRCT. All
34 patients had a consistent usual interstitial pneumonia
pattern. None of 34 patients received surgical lung bi-
opsy for definitive diagnosis. The 34 subjects with IPF
were predominantly men (73.5%). The median age was
69 years old. According to the GAP score, 22 patients
had stage I, 8 had stage II, and 4 had stage III disease,
and the subjects were considered to have had mild or
moderate disease at enrollment. The incidence of an AE
within 12 months from entry was 14.7%. There were 4
deaths reported among the 34 study participants in the
initial 12 months. Before the time of assessment, the
participants were undergoing treatment with clarithro-
mycin (n = 1), inhaled corticosteroids (n = 1) or antacids
(n = 10), respectively. None of the participants were tak-
ing systemic immunosuppressants, N-acetylcysteine or
antifibrotic agents at the time of entering this study.
During the observation period, the participants received
treatment with antifibrotic agents (n = 7), systemic corti-
costeroids (n = 4), cyclophosphamide (n = 2) and N-
acetylcysteine (n = 5) at some point. Table 1 also summa-
rises the information of the total cell counts in BALF.
Although the alteration in alveolar microbial flora is
often accompanied by changes in BALF cell counts, no
correlation was established between BALF cell counts
and the microbiome in this study.
The diversity of the lung microbiome was associated with
progression of IPF.
The number of tuf gene was measured instead of the
number of bacteria. Figure 1a shows the overall total
bacterial load measured in 1 ml of BALF, and values
ranged from 601 to 4554 (Fig. 1a). There was no statisti-
cally significant difference regardless of the history of AE
(Additional file 1: Figure S1). Overview of DNA sequen-
cing data are shown in Additional file 1: Table S1. The
number of OTUs and sequences reads per BALF sample
ranged from 56 to 93 and from 29,956 to 132,216 in the
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family level classification, respectively. Rarefaction
curves were calculated to measure how well the amount
of sequencing performed for a library represented the
biodiversity in the library, and the measured values
ranged from 0%–100%, with 100% indicating that all ex-
pected OTUs were observed, which would suggest that
deeper sequencing would be unlikely to identify add-
itional OTUs. The rarefaction curves in this analysis in-
dicated that sufficiently deep sequencing had been
achieved (Additional file 1: Figure S2). To evaluate the
microbial diversity in these subjects, the Shannon and
Simpson diversity indexes were examined. The values in
the Shannon diversity index ranged from 2.817 to 4.623.
Poor OTU diversity was obtained in three patients,
which had values of 2.817, 3.281, and 3.347. The Simp-
son diversity index ranged from 0.727 to 0.931, which
were parallel to the indices of the Shannon diversity
index (Fig. 1b and c). To examine whether the diversity
of the pulmonary microbiome influenced disease pro-
gression, we compared the diversity with the clinical
data of 30 patients in the non-deterioration group (n = 22)
and the deterioration group (n = 8; 7 had a − 10% or
greater decrease in FVC and 1 could not perform the
PFT) (Fig. 1d). In all patients within the deterioration
group (n = 8), the diversity index tended to be smaller
than that in the patients of the non-deterioration group.
Additionally, the diversity index was significantly smaller
in the early death populations than in the survival popula-
tions (Fig. 1e). These results suggested the possibility that
the diversity of the pulmonary microbiome could be used
to predict prognosis for IPF pathogenesis. The relative
abundances of bacterial phyla and family OTUs with
> 1.0% relative abundance per sample are shown in
Fig. 1f. The most dominant lung phyla found were
Firmicutes, Proteobacteria, Bacteroidetes, and Actino-
bacteria (37.4%, 29.4%, 19.8%, and 11.7%, respectively).
Additionally, we observed Cyanobacteria and Fusobacteria
in the lung. The largest and second largest family OTU in
the Firmicutes were the Streptococcaceae and Veillonella-
ceae (14.9% and 9.7%, respectively). The second largest
family OTU was Prevotellaceae (12.1%), which is a
member of the Bacteroidetes. Other common OTUs
identified in the family included Propionibacteriaceae,
Shewanellaceae, Pseudomonadaceae, and Staphylococ-
caceae. Considering the diversity more deeply, we
presumed that the decrease in diversity was due to an
increase in Firmicutes and a decrease in Proteobac-
teria. Particularly concerning Firmicutes, involvement
of the Streptococcaceae and Veillonellaceae families
was shown (Table 2).
Micro-organisms were associated with the clinical
biomarkers or physiological assessment.
Next, we evaluated correlations between clinical data
and microbiomes. The FVC was used as an index to
understand the progress of IPF, and we first focused on
the relationship between the FVC and pulmonary micro-
biome. We observed no significant association between
bacteria burden and FVC (ρ = − 0.153; P = 0.395). How-
ever, we found that the FVC decreased in inverse pro-
portion to the relative abundance of Firmicutes. On the
other hand, the relative abundance of Proteobacteria
closely paralleled the FVC results. At the family level,
the relative abundances of Streptococcaceae and Veillo-
nellaceae, the largest and second largest single OTU in a
member of the Firmicutes, was significantly associated
with a decline in FVC (Fig. 2a–d). Furthermore, the
Shannon diversity index was positively correlated with
Table 1 Baseline characteristics of the study patients
Age (years) 69 (63–72)
Sex M 25 (73.5%)
F 9 (26.5%)
Smoking History current or ex 27 (79.4%)
never 7 (20.6%)
GAP score I 22 (64.7%)
(Stage) II 8 (23.5%)
III 4 (11.8%)
SP-A (ng/ml) 77.0 (43.3–95.2)
SP-D (ng/ml) 217.0 (150.0–333.0)
KL-6 (U/ml) 972.0 (572.0–1440.0)
PaO2 (mmHg) 87.8 (80.7–91.6)
PaCO2 (mmHg) 40.2 (37.6–41.7)
AaDO2 12.6 (8.0–17.9)
FVC (L) 2.7 (2.1–3.2)
%FVC 93.0 (75.5–104.3)
FEV1 (L) 2.3 (1.9–2.6)
%FEV1 83.3 (76.9–88.2)
DLCO (ml/min/mmHg) 12.0 (10.1–15.4)
%DLCO 60.0 (52.4–76.1)
6MWD (m) 430 (365–480)
Minimum SpO2 (%) during 6MWT 93 (88–99)






CD4/8 (ratio) 2.0 (1.1–2.7)
n (%) or median ± IQR. DLCO, %DLCO; n = 31, other; n = 34. Definition of
abbreviations: FVC Forced vital capacity, %FVC Percent predicted FVC, FEV1
Forced expiratory volume in the first second, %FEV1 Percentage of predicted
FEV1, DLco Diffusing capacity of lung carbon monoxide, %DLco Percent
predicted DLCO, SP-A Surfactant protein A; SP-D Surfactant protein D; KL-6
Krebs von den Lungen-6; 6MWD 6-min walk distance; 6MWT 6-min walk test
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the FVC (Table 3). The diversity index from microbial
communities are also correlated to the serum level of
surfactant protein D (SP-D), lactate dehydrogenase
(LDH), and 6MWD, which are the clinical biomarkers or
physiological assessment of progression in IPF (Table 3).
The families of the Firmicutes phylum also correlated
with 6MWD and serum level of SP-D (Fig. 3a and b).
Bacterial burden demonstrated an inverse correlation
with 6MWD (ρ = − 0.347; P = 0.051). However, we estab-
lished no other obvious relationship between bacterial
burden and the clinical biomarkers or physiological as-
sessment. Taken together, these results showed that a
reduction in diversity caused by an increase in Firmi-
cutes (Streptococcaceae and Veillonellaceae families)
and a decrease in Proteobacteria correlated with disease
worsening, which indicated a possible contribution of
these organisms to IPF pathogenesis.
Microbiome was altered in bleomycin-induced lung
fibrosis.
Microbiomes are thought to be affected by various con-
founding factors such as smoking history, drugs, etc.
[18]. To investigate the clear relationship between
microbiome and pathological conditions, we examined
the microbiome in mice with the bleomycin-induced
lung fibrosis. BAL was performed at 28 days post bleo-
mycin, then representative photomicrographs are pre-
sented in Additional file 1: Figure S5. Histopathological
assessment showed that diffuse intra-alveolar fibrosis
and focally dense fibrosis at the sub-pleural region re-
sulted in increases in the number of cells, especially alveo-
lar macrophages, in BALF (Additional file 1: Figure S5).
Although the degree of fibrosis was slightly different in in-
dividual mice, all mice treated with bleomycin were in-
cluded in this analysis, irrespective of the degree of
fibrosis. There was no difference in total load of tuf gene
between the bleomycin-treated and saline-treated mice
(Fig. 4a). Conversely, the Shannon diversity index was
Fig. 1 a Total number of tuf gene was measured by real-time PCR. b, c The alpha diversity is shown by a box plot. d Shannon diversity index is
compared between IPF with or without deterioration. e IPF patients who died within 12 months had a significantly lower Shannon diversity index.
Box plots are expressed as the median ± IQRs, Mann–Whitney U test, *: p < 0.05. f Phylum and family level of operational taxonomic units from
16S rRNA gene sequences. Microbial subjects with > 1.0% relative abundance per sample are shown
Table 2 The relationships between diversity and the relative
abundance of bacteria
Shannon diversity index Simpson diversity index
ρ p-value ρ p-value
vs Firmicutes −0.5696 0.0004 ** −0.4599 0.0062 **
vs Proteobacteria 0.7635 < 0.0001 ** 0.6468 < 0.0001 **
vs Bacteroidetes −0.3744 0.0292 * −0.2567 0.1427
vs Streptococcuceae −0.3368 0.0515 −0.3035 0.0810
vs Veilonellaceae −0.3517 0.0413 * −0.2180 0.2154
vs Prevotellaceae −0.4359 0.0100 * −0.2656 0.1290
These OTUs had a strong impact on diversity in the lung. Spearman’s test. ρ:
Spearman rank-correlation coefficient, *: p < 0.05, **: p < 0.01
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significantly smaller in bleomycin-treated mice compared
to saline-treated mice. (Fig. 4b). The most dominant lung
phyla found were Firmicutes, Proteobacteria, Bacteroi-
detes, and Actinobacteria in saline-treated mice lungs
(49.9%, 20.9%, 10.9%, and 16.0%, respectively). In particu-
lar, a significant increase was confirmed in Firmicutes in
BALF from bleomycin-treated mice (p < 0.05) (Fig. 4c).
These results indicate that the alternation of the micro-
biomes in phylum on fibrotic changes is quite similar be-
tween the human samples and mice. Principal coordinate
analysis (PCoA) was performed to establish relationships
among all samples. The PCoA graph demonstrated that
the OTUs detected in BALF of bleomycin-treated mice
were well separated from that of saline controls, which
indicates that the microbial communities found in
bleomycin-treated mice were different from those in the
saline controls (Fig. 4d).
Discussion
In this study, we showed that BALF from initially diag-
nosed IPF contained microbiota and that the loss of diver-
sity of the lung microbiome correlated with the
progression of IPF. Regarding the change in lung micro-
biome diversity, we found that increases in the Firmicutes
and Bacteroidetes (Streptococcaceae, Veillonellaceae, and
Prevotellaceae families) and a decrease in the phylum Pro-
teobacteria were involved in the reduction of diversity.
Moreover, the loss of diversity correlated with IPF indica-
tors, including low FVC, decreased 6MWD, and high
serum SP-D and LDH. Unfortunately, there were no
healthy controls in this study, but loss of diversity in IPF
compare to healthy control was reported in a previous
paper [13]. Also, Molyneaux PL et al. suggested that the
bacterial communities of the lower airways act as persist-
ent stimuli for repetitive alveolar injury [19]. Taken to-
gether, loss of diversity might have some impact on the
pathogenesis of IPF. There is also a possibility that diver-
sity is related to the mortality rate and FVC decline 1 year
after diagnosis, which suggests that lung microbiome di-
versity may be a prognostic indicator, which is the most
crucial finding in this study. Furthermore, racial
Fig. 2 The relationships between FVC and relative abundance of bacteria. a Phylum Firmicutes, (b) Phylum Proteobacteria, (c) Family Streptococcaceae
and (d) Family Veillonellaceae. In each case, linear regression lines have been fitted. Spearman’s test. ρ: Spearman rank-correlation coefficient,
*: p < 0.05, **: p < 0.01
Table 3 Diversity statistics of pulmonary microbiomes with
clinical findings
Shannon diversity index Simpson diversity index
ρ p-value ρ p-value
vs FVC (L) 0.4280 0.0116 * 0.3757 0.0286 *
vs %FVC (%) 0.4948 0.0029 ** 0.4154 0.0145 *
vs 6MWD (m) 0.3716 0.0332 * 0.3509 0.0452 *
vs SP-D (ng/ml) − 0.4230 0.0127 * − 0.4538 0.0070 **
vs LDH (IU/L) −0.3283 0.0580 −0.3471 0.0443 *
Spearman’s test. ρ: Spearman rank-correlation coefficient, *: p < 0.05,
**: p < 0.01
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differences and environmental factors were also consid-
ered to be involved in the microbiome and obtaining simi-
lar results in Asia compared with Western countries was
significant. Additionally, we found that an increase in
Streptococcaceae correlated with a reduction in 6MWD
(Additional file 1: Figure S4). These results possibly sug-
gest that pulmonary microbiomes and lung fibrosis are
closely related and are involved in the pathogenesis of IPF.
In contrast, whether microbial changes are a cause or
merely a consequence of disease progression remains un-
clear. Hence, further extensive interventional studies, in-
cluding antibiotics treatment or vaccines to alter the lung
microbiome, are needed to elucidate this phenomenon.
Meanwhile, the examinations of microbiomes using
clinical samples are quite complicated, because there are
many confounding factors such as smoking history,
drugs, etc. So, we decided to verify our results of the
clinical samples using the bleomycin-treated mice with a
Fig. 3 Scatter plots show the correlations of the relative abundance of Firmicutes with (a) 6MWD and (b) serum SP-D. In each case, linear regression
lines have been fitted. Spearman’s test. ρ: Spearman rank-correlation coefficient, *: p < 0.05, **: p < 0.01
Fig. 4 Bleomycin-treated fibrosis alters microbiome in mice lung. C57BL/6 J mice were treated with bleomycin (Bleo) and normal saline (NS) solution
as described in methods. a Total number of tuf gene in BALF was measured by real-time PCR. b The alpha diversity was shown by a box plot. Box plots
are expressed as the median ± IQRs. Mann–Whitney U test. *: p < 0.05. c Phylum level of operational taxonomic units from 16S rRNA gene sequences.
Microbial subjects with > 1.0% relative abundance per sample are shown. d Two-dimensional PCoA plot of microbial communities in lung
from bleomycin- and saline-treated mice, indicated as significant by PERMANOVA (p = 0.0209). Axes show percentage of contribution, PC1:
50.1%, PC2: 23.7%
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uniform background, which is widely used in IPF stud-
ies. Since the living environment of the mice is very dif-
ferent from humans, their detailed bacterial flora was
expected to be different [20]. However, we found that
the relative changes in the bacterial communities accom-
panying fibrosis in the mice were quite similar to that in
IPF patients (Fig. 4c). The increase in the relative abun-
dance of Firmicutes and the decrease in that of Proteo-
bacteria, and its accompanying reduction in diversity
were observed in BALF from bleomycin-treated mice
(Fig. 4b and c). These results partly supported the ana-
lysis in the human specimens. Furthermore, PCoA ana-
lysis in the mice revealed that the microbial
communities under bleomycin-induced fibrosis were dif-
ferent from normal flora (Fig. 4d), which is not detected
in human subjects (data not shown). This may be due to
the fact that there are many confounding factors among
the patients as mentioned above. It is still difficult to
identify causative bacteria implicated in the progression
of IPF. Nonetheless, our data suggest that fibrotic
changes in the lungs are related to the alternations of
specific bacteria or the decline of diversity.
The Hokkaido study revealed that the most common
(40%) cause of death was an AE, which resulted in rapid
disease progression and a mortality rate of 80% [7]. As
the causes of AE, including whether or not bacteria are
involved, have not been determined, we believe that it is
essential to prove the effect of microbiomes on AEs.
Based on our examination at diagnosis, the occurrence
of an AE in the future was not related to an increased
total bacterial burden and the loss of diversity
(Additional File 1: Figure S1). However, because this
study highlighted the possibility of the effect of micro-
biomes on AEs [21–23], we intend to elucidate these
findings in our next larger prospective study. Further-
more, we believe that it is imperative to investigate the
causative bacteria on fibrosis in a murine model in the
future.
An imbalance in the host–microbial relationship is
thought to contribute to inflammation and immunity in
the IPF lung [24]. It is well known that the pulmonary col-
lectins, surfactant proteins A and D, have an important
role in the alveolar spaces and are useful biomarkers in
IPF [25]. In this study, serum SP-D was strongly associ-
ated with microbiome characteristics, including diversity,
the relative abundance of Firmicutes, Proteobacteria, and
Veillonellaceae. However, serum SP-A correlated poorly
with lung microbiomes in contrast to BALF SP-A
(Additional file 1: Figure S3). Our previous study reported
that serum levels of SP-D could reflect pathological
changes of IPF lungs more decisively than those of SP-A
[26]. Because the correlation between BALF SP-A and
Veillonellaceae is positive, SP-A production from alveolar
type II cells is thought to be increased by inflammatory
stimulation accompanying the increase in bacteria.
Taken together, it is possible that serum SP-A, in
contrast to BALF SP-A, did not correlate with the
microbiomes because SP-A remains bound to surfac-
tant lipids in the alveolar space. On the other hand,
SP-D reflects changes in the microbiome, such as di-
versity, because SP-D easily leaks into the blood-
stream. As described above, because pulmonary
collectins have an important role in pulmonary envi-
ronments, we plan to clarify the association between
the lung microbiome and the collectins in a future
study.
This study had some limitations. All participants in
this study satisfied the diagnostic criteria of IPF; how-
ever, because surgical lung biopsy was not performed
at the time of diagnosis, the possibility of including
other similar fibrotic diseases cannot be ruled out. In
addition, the number of participants (n = 34) was
small to evaluate the association between the micro-
biome and IPF pathogenesis, because there are many
confounding factors among IPF participants. For this
reason, the examination using mice was carried out
to prove the results of the human specimens by
avoiding the influence of the confounders, although
the etiology is somewhat different from IPF. Mice
study cannot prove or disprove human studies be-
cause of their distinctly different nature and environ-
ment; it can provide credence to human studies, but
cannot prove it. Furthermore, the inclusion of healthy
controls would have been ideal, but there were no
healthy controls in this study. Future studies using a
larger number of subjects with appropriate controls
are needed to further investigate the role of the
microbiome in IPF. Additionally, the presence or ab-
sence of emphysematous change and the degree or lo-
cation of fibrosis was not considered in this study. It
is possible that the microbiomes may change depend-
ing on the grade of fibrosis and honeycomb change.
Previous studies have shown that patients with some
respiratory past history have different microbiomes
than those of healthy volunteers [27]. Furthermore,
antibiotics, antacids, inhaled corticosteroids and nutri-
tious food, which can cause microbial changes, should
be considered. Because the possible effect of antacids
or inhaled corticosteroids on the microbiome cannot
be denied in this study. Technically, BAL was care-
fully performed to prevent contamination from the
upper respiratory tract because sampling of the air-
ways by bronchoscopy depends on inserting the bron-
choscope into the mouth. It is still possible that
contamination from the upper respiratory tract was
present; however, a previous report indicated that
contamination with oral microbiota from use of typ-
ical bronchoscopy techniques was limited [28].
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Conclusions
In summary, this study identified relationships between
the relative abundance of specific taxa in BALF and clin-
ical findings, such as the FVC, 6MWD, and serum SP-D.
Previous reports have shown that microbes were associ-
ated with IPF progression. Our data indicated that the
diversity of the pulmonary microbiomes might be a
prognostic factor of IPF pathogenesis. Bleomycin-
induced lung fibrosis in mice revealed the association
between microbiome and fibrotic changes, which also
supported the results in the human samples. Further
study of the lung microbiome may provide novel insights
into its possible contribution to IPF pathogenesis and
help identify new biomarkers.
Additional file
Additional file 1: Impaired Diversity of the Lung Microbione Predicts
Progression of Idiopathic pulmonary Fibrosis. Table S1. Overview of DNA
sequencing data. Figure S1. Comparison of the total bacterial genes
between the AE and non-AE groups. Figure S2. Rarefaction curves were
calculated, which suggests that all expected OTUs have been obsreved.
Figure S3. the concentration of SP-A in BALF correlates well with the
relative abundance of Veillonellaceae, but not serum SP-A. Figure S4.
The relative abundance of family Streptococcaceae also correlated with
6MWD. Figure S5. Histopathological assesment and BAL cell counts in
mice with the bleomycin-induced lung fibrosis. (PDF 7772 kb)
Abbreviations
%DLco: Percent predicted DLCO; %FEV1: Percentage of predicted FEV1;
%FVC: Percent predicted FVC; 6MWD: 6-min walk distance; AE: Acute
exacerbation; BAL: Bronchoalveolar lavage; BALF: Bronchoalveolar lavage
fluid; DLco: Diffusing capacity of lung carbon monoxide; FEV1: Forced
expiratory volume in the first second; FVC: Forced vital capacity; HRCT: High-
resolution computed tomography; IPF: Idiopathic pulmonary fibrosis;
OTU: Operational taxonomic units; PFT: Pulmonary function test; SP-A and
D: Surfactant protein A and D
Acknowledgements
We would like to express our gratitude towards Ms. LaSance Kathleen for
proofreading the English text.
Funding
This work was supported by Novartis Pharma Research Grants 2017 (to A. S.),
GSK Research Grants 2017 (to A. S.), and JSPS KAKENHI Grant Numbers
JP15K09181 (to K. K.).
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
A. S. and K. K. developed the concept and A. S. performed the experiments,
analyzed and interpreted the data, and wrote the manuscript. Y. T. performed
correcting the sample and created the clinical database. Y. S. carried out the
sequence analysis. H. C., K. I., T. K, S. A., M. T. and H. T. assisted with data analysis
and interpretation and supervised the statistical analysis. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Sapporo Medical University Hospital’s ethics
board (approval number, 292–35). All experiments using mice were conducted





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Respiratory Medicine and Allergology, Sapporo Medical
University School of Medicine, S1W16 Chuoku, Sapporo 060-8543, Japan.
2Department of Biochemistry, Sapporo Medical University School of
Medicine, S1W17 Chuoku, Sapporo 060-8556, Japan. 3Department of Medical
Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical
University, S1W17 Chuoku, Sapporo 060-8556, Japan.
Received: 15 November 2017 Accepted: 8 February 2018
References
1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV,
Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT
statement: idiopathic pulmonary fibrosis: evidence-based guidelines for
diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
3. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ,
du Bois RM. Long-term course and prognosis of idiopathic pulmonary
fibrosis in the new millennium. Chest. 2011;140:221–9.
4. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A,
King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in
patients with idiopathic pulmonary fibrosis: test properties and minimal
clinically important difference. Am J Respir Crit Care Med. 2011;184:1382–9.
5. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW,
Taniguchi H, Chiu C, Boushey H, et al. Viral infection in acute
exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med. 2011;183:1698–702.
6. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of
idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur
Respir J. 2011;37:356–63.
7. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, Bando M,
Sugiyama Y, Takahashi H. Epidemiologic survey of Japanese patients with
idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J
Respir Crit Care Med. 2014;190:773–9.
8. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE,
Zhang W, Gudmundsson G, Groshong SD, et al. A common MUC5B
promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:
1503–12.
9. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade
MS, Hysi P, Scuirba J, et al. Genetic variants associated with idiopathic
pulmonary fibrosis susceptibility and mortality: a genome-wide association
study. Lancet Respir Med. 2013;1:309–17.
10. Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung
diseases. Nat Rev Immunol. 2014;14:827–35.
11. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P,
Hansbro PM. Emerging pathogenic links between microbiota and the gut-
lung axis. Nat Rev Microbiol. 2017;15:55–63.
12. Shukla SD, Budden KF, Neal R, Hansbro PM. Microbiome effects on
immunity, health and disease in the lung. Clin Transl Immunology.
2017;6:e133.
13. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM,
Murphy E, Johnston SL, Schwartz DA, Wells AU, et al. The role of bacteria in
the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med. 2014;190:906–13.
14. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES,
Flaherty KR, Huffnagle GB, et al. Lung microbiome and disease progression
in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet
Respir Med. 2014;2:548–56.
Takahashi et al. Respiratory Research  (2018) 19:34 Page 9 of 10
15. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli
M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for
idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684–91.
16. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y,
Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary
fibrosis. Eur Respir J. 2010;35:821–9.
17. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA,
Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.
18. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the
respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;
15:259–70.
19. Molyneaux PL, Willis Owen SA, Cox MJ, James P, Cowman S, Loebinger M,
Blanchard A, Edwards LM, Stock C, Daccord C, et al. Host-microbial
interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;
20. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD,
Nicod LP, Lloyd CM, Marsland BJ. Lung microbiota promotes tolerance to
allergens in neonates via PD-L1. Nat Med. 2014;20:642–7.
21. Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, Moffatt MF,
Kim DS, Maher TM. Changes in the respiratory microbiome during acute
exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017;18:29.
22. Lok SS, Haider Y, Howell D, Stewart JP, Hasleton PS, Egan JJ. Murine
gammaherpes virus as a cofactor in the development of pulmonary fibrosis
in bleomycin resistant mice. Eur Respir J. 2002;20:1228–32.
23. Knippenberg S, Ueberberg B, Maus R, Bohling J, Ding N, Tort Tarres M,
Hoymann HG, Jonigk D, Izykowski N, Paton JC, et al. Streptococcus
Pneumoniae triggers progression of pulmonary fibrosis through
pneumolysin. Thorax. 2015;70:636–46.
24. Huang Y, Ma SF, Espindola MS, Vij R, Oldham JM, Huffnagle GB, Erb-
Downward JR, Flaherty KR, Moore BB, White ES, et al. Microbes associate
with host innate immune response in idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med. 2017;
25. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y,
Shiratori M, Kuroki Y, Abe S. Serum surfactant proteins a and D as
prognostic factors in idiopathic pulmonary fibrosis and their relationship to
disease extent. Am J Respir Crit Care Med. 2000;162:1109–14.
26. Nishikiori H, Chiba H, Ariki S, Kuronuma K, Otsuka M, Shiratori M, Ikeda K,
Watanabe A, Kuroki Y, Takahashi H. Distinct compartmentalization of SP-A
and SP-D in the vasculature and lungs of patients with idiopathic
pulmonary fibrosis. BMC Pulm Med. 2014;14:196.
27. Segal LN, Clemente JC, Tsay JC, Koralov SB, Keller BC, Wu BG, Li Y, Shen N,
Ghedin E, Morris A, et al. Enrichment of the lung microbiome with oral taxa
is associated with lung inflammation of a Th17 phenotype. Nat Microbiol.
2016;1:16031.
28. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD,
Collman RG. Topographical continuity of bacterial populations in the healthy
human respiratory tract. Am J Respir Crit Care Med. 2011;184:957–63.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Takahashi et al. Respiratory Research  (2018) 19:34 Page 10 of 10
